Antibe Therapeutics Inc(Pre-Merger) ATBPF

AME study results

[Edou111]

Could negative AME study results leaked and brought the Share Price down ?

[Inthepez]

They’re still underway. 4 more weeks to go. It’s uniformed people like you who panic sell. Idc if you do, but stop asking dumbass questions with leaks and nonsense. 

[StockingUp21]

how else can explain selling and lower every day? Something very wrong makes more sense then pumpers saying this is normal to lose 50% in couple months.  

[Inthepez]

I know you !diots lack imagination and think that “stonks go up”, so current SP can be explained like this: most common shares are owned by retail. The retail shareholder is notorious for swing trades. Nothing on the horizon for ate. No catalysts for a few months and retail will lose interest, Opportunity cost wise, there are much better plays for retail investors. Fundamentals haven’t changed

[Edou111]

Dear InthePez As "dumb" as it might appear, I have been investing in pharma /bio stocks for more than a decade and have seen this scenario too many times...Overreacting is no good for the inflammation in your body !  Take care !

[Inthepez]

Always hilarious to see rubes mistake valid criticism as an “overreaction”. It is dumb to think info “leaked”  in the AME study, when it barely started. 

[IrishCanuck]

Whether pumping or dumping, we should be able to find common ground that it was a stupid statement. Once we agree on that then we know we're in the same universe. 

[GameChangerBet]

If there was a leak about anything major negative, stock would go from $4 to $2, not $4 to $3.60, the drop would be sudden and severe, not gradual. We're seeing nothing but retail impatience, as well as opportunities elsewhere for the immediate moment to make money, also perhaps the brokerage boys in the back dipping their hands where and when they can in the meantime to extract $$ in this

[MrMugsy]

Which scenario have you seen too many times ? The one where the share price isn't in line with the value of the company (I too have seen that many times) OR "Adverse events across the three doses of ATB-346 were similar to placebo, with very few serious adverse events or events leading to withdrawl of treatment.  Adjucating for patient-specific factors reflected a liver safety

[123ABC]

How's that a dumb question? Why are you so angry?

[WalkOverTheStrt]

Seriously? It's not only a dumb question it's intended to fear monger. AME per the the 28 June pr (below) was scheduled to start on 05 July... It is 13 July. Rresults are expected by year end.  So since the share price is eroding the only hypothesis is to point at the AME study? Not the fact the stock is thinly traded, that it is mostly owned by retail who are fickle, that we

[Edou111]

Lots of folk bashed me when I wrote this...

[AntibeTrash]

Pumpers are a different breed of human, don't pay too much attention to them.

[WalkOverTheStrt]

YYou get that just b/c the AME study had an issue doesn't necessarily correlate to your post / theory on 13 July which would have been only two or so weeks into the trial (PH2 was 2 weeks)... let alone you were implying the price decline (which shockingly has been correlated to the XBI) that was occuring days and weeks before the AME trial started. all patients of the 42 had been dosed for a

[Edou111]

This was known from a long time ago.  Isn't it why this AME studies were conducted ?  Why do you think insiders were not buying ? The LTEs will need to be considered moving forward, but are manageable from a clinical perspective. Given the robust upper portion of the dose-response curve, we anticipate lower doses will be effective and further optimize the safety profile of ATB-346,

[Edou111]

Lots of folk bashed me when I wrote this... Reply Quot